0001209191-18-054397.txt : 20181005
0001209191-18-054397.hdr.sgml : 20181005
20181005163731
ACCESSION NUMBER: 0001209191-18-054397
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181004
FILED AS OF DATE: 20181005
DATE AS OF CHANGE: 20181005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tullman Stephen A.
CENTRAL INDEX KEY: 0001654343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 181110911
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 101 LINDENWOOD DRIVE, SUITE 400
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-04
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001654343
Tullman Stephen A.
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
1
0
0
0
Common Stock
2018-10-04
4
P
0
7100
13.9958
A
177457
D
Common Stock
394014
I
By Trust
The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018.
This transaction was executed in multiple trades at prices ranging from $13.90 to $14.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which the reporting person's spouse serves as the trustee.
/s/ Mark Ballantyne, Attorney-in-fact
2018-10-05